Version 1
: Received: 5 August 2023 / Approved: 7 August 2023 / Online: 8 August 2023 (03:37:15 CEST)
Version 2
: Received: 8 August 2023 / Approved: 9 August 2023 / Online: 10 August 2023 (08:37:05 CEST)
Zenunaj, G.; Acciarri, P.; Baldazzi, G.; Cosacco, A.M.; Gasbarro, V.; Traina, L. Endovascular Revascularisation versus Open Surgery with Prosthetic Bypass for Femoro-Popliteal Lesions in Patients with Peripheral Arterial Disease. J. Clin. Med.2023, 12, 5978.
Zenunaj, G.; Acciarri, P.; Baldazzi, G.; Cosacco, A.M.; Gasbarro, V.; Traina, L. Endovascular Revascularisation versus Open Surgery with Prosthetic Bypass for Femoro-Popliteal Lesions in Patients with Peripheral Arterial Disease. J. Clin. Med. 2023, 12, 5978.
Zenunaj, G.; Acciarri, P.; Baldazzi, G.; Cosacco, A.M.; Gasbarro, V.; Traina, L. Endovascular Revascularisation versus Open Surgery with Prosthetic Bypass for Femoro-Popliteal Lesions in Patients with Peripheral Arterial Disease. J. Clin. Med.2023, 12, 5978.
Zenunaj, G.; Acciarri, P.; Baldazzi, G.; Cosacco, A.M.; Gasbarro, V.; Traina, L. Endovascular Revascularisation versus Open Surgery with Prosthetic Bypass for Femoro-Popliteal Lesions in Patients with Peripheral Arterial Disease. J. Clin. Med. 2023, 12, 5978.
Abstract
Aim. Atherosclerotic complex femoropopliteal lesions have traditionally been treated with bypass surgery. A prosthetic graft is used to save the vein graft for more distal revascularization or when unavailable. However, the endovascular approach has gained popularity and is offered as first-line strategy for complex lesions. This study aimed to evaluate whether endovascular procedures for complex femoropopliteal native lesions can be a first-line treatment strategy over open surgery with prosthetic bypass in patients with peripheral arterial disease (PAD). Methods. A retrospective study was conducted between 2013 and 2021 to identify patients with symptomatic PAD who required limb revascularization at the femoropopliteal segment and complex lesions (TASC II C and D). Primary endpoints were technical success, primary patency, freedom from clinically driven target lesion revascularization (cdTLR), freedom from major adverse limb and cardiovascular events (MALE and MACE), freedom from limb loss, and survival. Secondary endpoints were length of in-hospital stay, duration of the procedure, and costs. Results. We identified 185 limbs among 174 suitable candidates for comparison, wherein 105 were treated with endovascular procedure and 80 with femoral popliteal prosthetic bypass. Most patients in both groups presented with chronic limb-threatening limb ischemia, and all were ASA >3. There were more octogenarians (p = 0.02) and patients with coronary disease (p = 0.004) in the endovascular group. Median follow-up was 30 months. Technical failure rate for endovascular procedures was 4.8% vs 0% in the open group (p 0.003). Freedom from MACE was similar in both groups. The endovascular group showed superior primary patency (p<0.0001), cdTLR (p<0.0001), MALE (p<0.0001), and freedom from limb loss (p = 0.0018) at 24 months. Further analysis performed for the open above-the-knee subgroup showed that the aforementioned endpoints were similar at 12 months, and favoured the endovascular group at 24 months. Procedural time and in-hospital stay were longer in the open group (p<0.0001 and p<0.001). Finally, procedural cost was 10-fold lower in the endovascular bypass group than in the prosthetic bypass group. Conclusion. Endovascular procedures for complex femoropopliteal lesions are safe in patients at high risk for surgery and show better outcomes at 24 months than prosthetic bypasses. The latter may be considered as an alternative in cases of endovascular failure.
Public Health and Healthcare, Public Health and Health Services
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Received:
10 August 2023
Commenter:
Gladiol Zenunaj
Commenter's Conflict of Interests:
Author
Comment:
I made the following changes: 1- Modified the last name of one of the co-authors. Dr. Cosaco to Cosacco 2- Shortened the description of the Table 3 and added the citation in the main text
Commenter: Gladiol Zenunaj
Commenter's Conflict of Interests: Author
1- Modified the last name of one of the co-authors. Dr. Cosaco to Cosacco
2- Shortened the description of the Table 3 and added the citation in the main text